Dr. Katerina Gurova came to Roswell Park Cancer Institute (RPCI) from Cleveland BioLabs, where she served as Director of Anti-Cancer Drug Discovery. Before joining Cleveland BioLabs, she worked as a Project Scientist in the Department of Molecular Genetics at The Cleveland Clinic.
Dr. Gurova earned her medical degree from the Sechenov Medical Academy and a doctoral degree in experimental oncology from the Blokhin Cancer Research Center, both located in Moscow, Russia.
Dr. Gurova’s research interests are focused on the discovery and development of new anticancer drugs. Specifically, she identified a new class of prospective anticancer agents named curaxins which are capable of simultaneous targeting of several signal transduction pathways that are frequently deregulated in cancer, including p53 and NF-kappaB. Her laboratory at RPCI is working on deciphering molecular mechanisms, optimizing therapeutic properties of curaxins and on the development of new approaches to treatment of hormone-refractory prostate cancer.
Dr. Gurova is a member of the American Association for Cancer Research.
Dr. Gurova has authored several research articles and reviews on the mechanisms of cancer cell death. For a complete list of publications click here.
Major goal of our lab is the discovery of new anti-cancer agents through different approaches, their testing and early stage development as well as understanding the mechanisms of their activity. We have molecules at different stage of development, including one, curaxin CBL0137, in clincial trial.
Our current focus area is chromatin remodeling factors, their role in normal development and disease, DNA damage detection and prevention. Specifically we are concentrated right now on a Facilitates Chromatin Transcription (FACT) complex. We have found that it may be used as a marker of aggressive poorly differentiated cancers with low overall survival. We are in the process of validation of FACT as an anti-cancer target through identification and testing of chemical FACT inhibitors and genetically modified mice to see consequences of FACT inhibition for tumors and the whole organism.
We also believe that FACt may be involved in the protection of our genome from DNA damage through the control of DNA topology. FACT can detect abnormal or alternative DNA structures and convey signal to p53 activation. Thus FACT has been a sensor and mediator of a novel type of cell stress-DNA superhelical or torsional stress, which is the situation when DNA is over or undertwisted, and may result in DNA breaks.
Additional area of research in the lab is cell and tissue specific response to DNA damage and p53 activation. We have identified small molecules which induce DNA damage and p53 response only in breast and prostate tumor cells and we are trying to understand their mechanism of action.
Gasparian AV, Neznanov N, Jha S, Galkin O, Moran JJ, Gudkov AV, Gurova KV, Komar AA. Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugs. Journal of virology 2010; 84(18):9390-9397
Gurova K, Gudkov AV. Targeting transcriptional regulators for simultaneous modulation of p53 and NF-kappa B in cancer treatment. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:1418
Burkhart CA, Gudkov AV, Norris MD, Marshall GM, Sartorelli AC, Gurova KV, Komarov PG, Isachenko N, Purmal A, Smith J, Flemming C, Xue C, Prokvolit A, Pajic M, Murray J, Watt F, Haber M. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer research 2009;69(16):6573-6580
Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 2009; 28(8):1151-1161
Gurova K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future oncology (London, England) 2009; 5(10):1685-1704
Narizhneva NV, Tararova ND, Ryabokon P, Shyshynova I, Prokvolit A, Komarov PG, Purmal AA, Gudkov AV, Gurova KV. Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell cycle (Georgetown, Tex.) 2009;8(24):4155-4167
Neznanov N, Fairchild RL, Almasan A, Banerjee AK, Gasparian AV, Gurova KV, Komarov AP, Neznanova L, Gorbachev AV, Gudkov AV. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell cycle (Georgetown, Tex.) 2009; 8(23):3960-3970
Logunov DY, Ginzburg AL, Naroditsky BS, Burdelya LG, Tararova ND, Gurova KV, Rakovskaya IV, Shmarov MM, Zubkova OV, Scheblyakov DV, Gudkov AV.Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene 2008;27(33):4521-4531
Tararova ND, Narizhneva N, Krivokrisenko V, Gudkov AV, Gurova KV. Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate 2007; 67(16):1801-1815
Xue C, Haber M, Flemming C, Marshall GM, Lock RB, MacKenzie KL, Gurova KV, Norris MD, Gudkov AV. P53 Determines Multidrug Sensitivity of Childhood Neuroblastoma. Cancer research 2007; 67(21):10351-10360
Gasparian AV, Gudkov AV, Komar AA, Veith J, Koman IE, Sviridov S, Safina A, Pal S, Guryanova OA, Commane M, Bosykh DA, Saranadasa M, Pal M, Brodsky L, Purmal AA, Burkhart CA, Gurova KV. Curaxins: anticancer compounds that simultaneously suppress NF-kappaB and activate p53 by targeting FACT. Science translational medicine 2011; 3(95):95ra74
Gudkov AV, Gurova KV, Komarova EA. Inflammation and p53: A Tale of Two Stresses. Genes and cancer 2011; 2(4):503-516
Saito NG, Woods DA, Gurova KV, Gudkov AV. Radiation sensitization by a small molecule that simultaneously suppresses NF-kappa B and activates p53.Proceedings of the American Association for Cancer Research Annual Meeting2008; 49:1002
Gorbachev AV, Gasparian AV, Gurova KV, Gudkov AV, Fairchild RL.Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation. European journal of immunology 2007;37(8):2257-2267
Garcia H, Fleyshman D, Kolesnikova K, Safina A, Commane M, Paszkiewicz G, Omelian A, Morrison C, Gurova K. Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells. Oncotarget2011; 2(10):783-796
Jung K-J, Dasgupta A, Huang K, Jeong S-J, Pise-Masison C, Gurova KV, Brady JN. Small-molecule inhibitor which reactivates p53 in human T-cell leukemia virus type 1-transformed cells. Journal of virology 2008; 82(17):8537-8547
Koman IE, Commane M, Paszkiewicz G, Hoonjan B, Pal S, Safina A, Toshkov I, Purmal AA, Wang D, Liu S, Morrison C, Gudkov AV, Gurova KV. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice. Cancer prevention research (Philadelphia, Pa.) 2012; 5(8):1025-1035